Introduction
Hematopoietic growth factors are actively involved in the regulation of the cellular proliferation, differentiation, survival, and functions in a variety of hematopoietic cells. The cloning of these human growth factors and their cognate receptors has enabled analysis of their precise roles. Human granulocyte colony-stimulating factor (G-CSF) was cloned 1 and recombinant human (rh) G-CSF is now commonly used in leukemic patients to promote recovery of severe neutropenia after intensified chemotherapy. 2 For clinical use of recombinant growth factors to leukemic patients, it is important to determine their effects on the proliferation of leukemic cells. The expression of G-CSF receptor (G-CSFR) on acute myelogenous leukemia (AML) cells [3] [4] [5] [6] [7] [8] and their G-CSF-induced proliferation in vitro 4, 6, 7 and in vivo 9 have been well documented. It has also been reported that G-CSF is able to support the survival, proliferation, and differentiation of multipotential hematopoietic stem cells, [10] [11] [12] suggesting that G-CSF may facilitate the proliferation of leukemic cells originated from hematopoietic stem cells, as well as from myeloid precursors.
We have recently shown that leukemic cells with 11q23 translocations, which are considered to arise from the multipotential hematopoietic stem cells, express G-CSFR and their proliferation is frequently stimulated with G-CSF. 13 Philadelphia chromosome (Ph1)-positive leukemias are also known to have their origin in hematopoietic stem cells. [14] [15] [16] [17] [18] [19] These leukemias are refractory to the standardized treatment regimens, 17, 20 and the most intensified chemotherapy and/or hematopoietic stem cell transplantation is required to improve their prognosis. Accordingly, G-CSF is currently used for severe neutropenia following the cytoreductive therapy in patients with Ph1-positive leukemia. To date, however, little is known about the biological effects of G-CSF on Ph1-positive leukemia cells, although expression of G-CSFR and proliferative response to G-CSF have been reported in a limited number of Ph1-positive leukemia cases. 21, 22 In the present study, we demonstrated that the blast cells from Ph1-positive leukemia patients and Ph1-positive leukemia cell lines expressed G-CSFR and their proliferation particularly of 'biphenotypic' type was stimulated with G-CSF. We also demonstrated that Ph1-positive leukemic cell lines particularly of 'myeloid' type produced G-CSF and their proliferation was partially inhibited by anti-G-CSF monoclonal antibody, suggesting an autocrine growth mechanism via the G-CSF/G-CSFR interaction.
Materials and methods

Patient samples and normal granulocytes
Three patients with chronic myeloid leukemia in blast crisis (CML-BC), seven patients with Ph1-positive acute lymphoblastic leukemia (ALL), and nine patients with Ph1-negative common (c) ALL were included in this study. The informed consent for the use of their samples for the study was obtained from all of patients or their parents. The rearrangement of minor bcr (m-bcr) in the bcr gene was found in four Ph1-positive ALL cases, while the rearrangement of major bcr (M-bcr) in three CML-BC and three Ph1-positive ALL cases (Table 1) . Bone marrow aspirates or peripheral blood samples, which contained Ͼ90% leukemic blasts, were obtained from these patients, and mononuclear cells were isolated by FicollHypaque density centrifugation. After centrifugation, all samples contained Ͼ95% leukemic blasts and cell viability was always Ͼ95%. Normal granulocytes were also isolated from peripheral blood of healthy volunteers using dextran sedimentation followed by Ficoll-Hypaque density centrifugation.
A total of 12 Ph1-positive leukemic cell lines were used in this study. K562 23 and NALM-1 24 were established from patients with erythroid and lymphoid crises of CML, respectively. Other cell lines have been established in our laboratory. 25 KOPM-28, 26 KOPM-53, KOPN-55bi, and KOPN-67 were established from CML-BC cases rearranged in M-bcr, while KOPM-30, KOPN-30bi, KOPN-57bi, KOPN-66bi, and KOPN-72bi were from Ph1-positive ALL cases rearranged in m-bcr. YAMN-73 was established from a patient with Ph1-positive ALL expressing the abl exon 2-spliced BCR-ABL (203 kDa) protein. 27 KOPM-30 and KOPN-30bi were established from the same patient at different stages of the disease. 28 As summarized in Table 2 , these cell lines were classified into one of the three groups based on cytochemistry and immunophenotype; 'myeloid' type positive for myeloperoxidase (pox) or expressing myeloid antigens (K562, KOPM-28, KOPM-30, KOPM-53), 'biphenotypic' type negative for pox but expressing both myeloid and immature B-lymphoid antigens (KOPN-30bi, KOPN-55bi, KOPN-57bi, KOPN-66bi, KOPN-72bi), and 'lymphoid' type negative for pox and expressing immature B-lymphoid antigens only (NALM-1, KOPN-67, YAMN-73). As controls, KOPT-5, a CD3 positive T cell leukemic cell line, and YAM-B1, an Epstein-Barr virus (EBV) transformed B cell line were used. All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) in a fully humidified atmosphere of 5% CO 2 at 37°C.
Immunophenotype analysis
Immunophenotypic analysis of patients' samples and cell lines was performed by indirect immune-rosette method 29 or flow cytometry. Monoclonal antibodies (mAbs) used in this study were shown in parentheses: CD1 (T6), CD2 (T11), CD3 (T3), CD4 (T4), CD5 (T1), CD7 (Tp40), CD8 (T8), CD10 (J5), CD11b (Leu15), CD13 (My7), CD14 (My4), CD19 (B4), CD20 (B1), CD21 (B2), CD22 (Leu14), CD25 (IL-2R1), CD33 (My9), CD34 (HPCA-2), CD36 (OKM5), CD41 (TP80), CD56 (NKH-1), glycophorin A (KOR-E6), and HLA-DR (12) . Leu14, Leu15, and HPCA-2 were purchased from Beckton-Dickinson (San Jose, CA, USA). TP80 was a kind gift from Dr Ryuzo Ueda (Department of Internal Medicine, Medical School, Nagoya City University, Nagoya, Japan). KOR-E6 was produced in our laboratory. 30 The other mAbs were purchased from Coulter Immunology (Hialeah, FL, USA).
G-CSFR assay
Recombinant human G-CSF (rhG-CSF) was kindly provided by Chugai Pharmaceutical (Tokyo, Japan). To detect the G-CSFR, biotinylated G-CSF was first produced as reported previously. 8, 31 In brief, 0.5 ml of G-CSF solution (500 g/ml) dialyzed against sodium bicarbonate (0.2 m, pH 8.4) was mixed with 25 l of biotinyl N-hydroxysuccinimide ester (Sigma Chemical, St Louis, MO, USA) in dimethyl sulfoxide (10 mg/ml), and incubated at room temperature for 4 h and at 4°C overnight. The G-CSF solution was dialyzed against PBS twice. The final concentration of biotinylated G-CSF was 200 ng/l.
One million mononuclear cells or leukemic cells were well washed with PBS and incubated with 2 l of biotinylated GLeukemia CSF. As a negative control, 100-fold excess of unlabeled G-CSF was also added. After incubation for 60 min at 4°C, the cells were washed twice with ice-cold PBS in the presence of 0.05% sodium azide and then incubated with streptavidinphycoerythrin (Biomeda, CA, USA) for 30 min at 4°C. These cells were washed and analyzed using a flow cytometry (EPICS Profile Analyzer, Coulter).
The channel of log fluorescence intensity was determined in each of samples above which 5% of cells for negative control were included, and the populations appearing above this channel were considered as positive in G-CSFR assay. 32 
Thymidine uptake assay
Mononuclear cells separated from patients were cultured in triplicate in 200 l of RPMI 1640 medium supplemented with 10% FCS in a flat-bottomed 96-well plate (Costar, Cambridge, MA, USA) at 1 × 10 5 cells/well in the absence or presence of various concentrations of rhG-CSF (1, 10, 100 ng/ml). In leukemic cell lines, the cells (1 × 10 4 to 1 × 10 5 cells/well) were cultured similarly in the absence or presence of various concentrations of rhG-CSF (0.1, 1, 10, 100 ng/ml). The plates were incubated for 48 h, pulsed for 6 h with 3 H-thymidine (1 Ci/well), and harvested on to glass-fiber filters. Radioactivity incorporated into DNA was measured by liquid scintillation counting. A stimulation index (SI) was also calculated as the ratio of the maximal In some experiments, a neutralizing mAb against G-CSF
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(kindly provided by Chugai Pharmaceutical) was added to wells at a final concentrations of 0.1, 1, and 10 g/ml, and 3 H-thymidine incorporation assay was similarly performed. Effects of anti-G-CSF mAb (10 g/ml) on 3 H-thymidine uptake were also tested in DMEM/F12 serum-free medium as well as in RPMI 1640 medium supplemented with 10% FCS in the absence or presence of exogenously added rhG-CSF (10, 100 ng/ml). The % inhibition was calculated as follows:
Measurement of intracellular G-CSF
After washing twice with PBS, leukemic cell lines were suspended in pure water (1 × 10 9 cells/ml), frozen in liquid nitrogen, and then thawed. This procedure was repeated three times and supernatants were obtained for analysis after removal of insoluble materials by centrifugation at 4°C for 15 min at 10 000 g. Intracellular G-CSF was first measured by enzyme immunoassay (EIA). 34 The samples less than 30 pg/ml of G-CSF were measured again by chemiluminescent enzyme immunoassay (CLEIA) which is more sensitive than EIA. 35 
Changes in morphology and surface antigens expression by G-CSF under suspension culture
Leukemic cell lines were cultured in RPMI-1640 supplemented with 10% FCS in the absence or presence of rhG-CSF (10 ng/ml). Cultures were started in flat-bottomed six-well plates (4 × 10 6 cells/8 ml). The morphology of the cells was observed every 3 days (up to day 12) on cytospin smears after Leukemia Wright-Giemsa staining. Surface antigens (CD19, CD13, CD14, CD33) expression was also examined every 3 days (up to day 12) by direct immunofluorescence using a flow cytometer.
Statistical methods
Comparison of
3 H-thymidine uptake in the presence or absence of G-CSF was based on paired t-test. Mann-Whitney test was performed for comparison of stimulation index and G-CSFR expression in patients' samples or leukemic cell lines. P value Ͻ0.05 was considered as significant. Correlation between the % inhibition by anti-G-CSF mAb and the amount of intracellular G-CSF was studied using linear regression analysis.
Results
Proliferative response to G-CSF and G-CSFR expression in the blast cells from patients with Ph1-positive leukemia
First, to determine whether the proliferation of the blasts from patients with Ph1-positive leukemia is stimulated by G-CSF in vitro, we performed 3 H-thymidine incorporation assays in the presence or absence of G-CSF using patients samples, all of which contained more than 95% leukemic blasts. As summarized in Table 1 , DNA synthesis was significantly increased in response to G-CSF in three CML-BC cases and three of seven Ph1-positive ALL cases (SI = 1.5-4.0). Cases 1, 2, 5, and 6 showed maximum response at 1 ng/ml of G-CSF, while cases 3 and 4 at 10 ng/ml. Thus, all of the cases responsive to G-CSF showed a significant proliferative response in vitro at the concentration corresponding to a range of that in peripheral blood when G-CSF is clinically administered. 36 In contrast, the blasts from nine cALL patients did not show significant response to G-CSF. The mean SI was 3.0 (2.0-4.0) in CML-BC, 1.4 (0.8-2.7) in Ph1-positive ALL, while 1.0 (0.6-1.4) in cALL. The SI of both CML-BC and Ph1-positive ALL cases was significantly higher than that of cALL cases (CML-BC vs c-ALL, P = 0.01; Ph1-ALL vs c-ALL, P = 0.04) by Mann-Whitney test. It should be noted that, in case 1 (CML-BC) and cases 4 and 6 (Ph1-positive ALL), the leukemic cells expressed only immature B-lymphoid antigens, suggesting that proliferative response of Ph-1 positive leukemia cells to G-CSF might not be dependent on their myeloid features. We next attempted to examine the G-CSFR expression on patients' leukemic cells. However, due to limited availability of cells for further analysis, only two cases of Ph1-ALL could be evaluated. As shown in Figure 1a , G-CSFR was detected in both cases 5 (G-CSF sensitive) and 8 (G-CSF insensitive), but their expression level was relatively lower (case 5; 26%, case 8; 42%) than that of normal granulocyte. The EBV transformed B cell line used for a negative control did not express G-CSFR at all.
Expression of G-CSFR on Ph1-positive leukemic cell lines
The data obtained from clinical samples suggested that Ph1-positive leukemia cells express G-CSFR and their proliferation is frequently stimulated with G-CSF, although the number of samples for study was limited. Because of difficulty in getting a large number of cells for further analysis from clinical samples and in completely eliminating the contaminated normal immature myeloid cells capable of responding to G-CSF, we next performed similar experiments using a total of 12 Ph1-positive leukemic cell lines listed in Table 2 . As shown in Table 3 , all Ph1-positive leukemic cell lines expressed G-CSFR. Flow cytometric histograms of representative Ph1-positive leukemic cell lines and a CD3 positive T cell leukemic cell line (negative control) were shown in Figure 1b . The percentage of G-CSFR positive cells was 15% to 37% (mean 22%) in 'myeloid' cell lines, 26% to 89% (mean 48%) in 'biphenotypic' cell lines, and 13% to 54% (mean 34%) in 'lymphoid' cell lines. As shown in Table 3 , the % G-CSFR in 'biphenotypic' cell lines was significantly (P = 0.04) higher than that in 'myeloid' cell lines. There was no significant difference in the % G-CSFR between cell lines established from CML-BC and those from Ph1-positive acute leukemia. 
Proliferative response of Ph1-positive leukemic cell lines to G-CSF
We next studied proliferative response of Ph1-positive leukemic cell lines to G-CSF by 3 H-thymidine incorporation assays. As summarized in Table 3 , the significant response to G-CSF was observed in all 'myeloid' and 'biphenotypic' cell lines and in two of three 'lymphoid' cell lines. The SI of different concentrations of G-CSF was shown in Figure 2 . Most 'myeloid' and 'biphenotypic' cell lines demonstrated a maximal response at 1-10 ng/ml of G-CSF which corresponds to a range of concentrations in peripheral blood of patients receiving G-CSF. 36 The mean of maximal SI was 1.29 (1.23-1.32) in 'myeloid' cell lines, 2.06 (1.58-2.83) in 'biphenotypic' cell lines, and 1.13 (1.08-1.16) in 'lymphoid' cell lines. As summarized in Table 3 , the most pronounced effect was observed in 'biphenotypic' cell lines (vs 'myeloid' cell lines, P = 0.02; vs 'lymphoid' cell lines, P = 0.03). Unexpectedly, 'myeloid' cell lines demonstrated only modest G-CSF response, although their response was higher than that of 'lymphoid' Leukemia cell lines (P = 0.03). There was no statistical correlation between the % G-CSFR and SI in each of the cell lines. Although, in analysis of clinical samples, CML-BC cases showed higher response to G-CSF compared with Ph1-positive ALL cases, no significant difference in SI was observed between cell lines established from CML-BC and those from Ph1-AL.
Inhibitory effect of anti-G-CSF mAb on proliferation of Ph1-positive leukemic cell lines
To test the possibility that some cell lines might be activated by endogenously produced G-CSF, we examined the effect of anti-G-CSF mAb on proliferation of Ph1-positive leukemic cell lines. The addition of anti-G-CSF mAb in culture substantially reduced 3 H-thymidine incorporation in a dose-dependent manner, maximal % inhibition greater than 20% in three of four 'myeloid', two of five 'biphenotypic', and one of three 'lymphoid' cell lines as indicated in Figure 3 and summarized in Table 3 . In particular, the maximal % inhibition was as high as 47% and 38% in 'myeloid' cell lines KOPM-28 and KOPM-30, respectively. This inhibitory effect of anti-G-CSF mAb proved to be specific, since non-relevant antibodies (both anti-CD3 and anti-IL-2 mAbs) have no effect on the proliferation of leukemic cell lines. Moreover, inhibition by anti-G-CSF antibody on the growth of KOPM-30 and KOPN-55bi was also observed in experiments using serum-free medium and was overcome by exogenously added G-CSF in a dose-dependent fashion (Figure 4) . These results suggested a positive autocrine loop via the G-CSF/G-CSFR interaction in Ph1-positive leukemia particularly of 'myeloid' type.
Production of G-CSF in Ph1-positive leukemic cell lines
To add further evidence for an autocrine mechanism via G-CSF/G-CSFR interaction, we measured endogenous production of G-CSF in Ph1-positive leukemia cell lines. As shown in Table 3 , amounts of intracellular G-CSF were higher than 100 pg/1 × 10 9 cells in three 'myeloid' types whose proliferation was markedly inhibited by anti-G-CSF mAb, and were higher than a detection limit of EIA (30 pg/1 × 10 9 cells) in three 'biphenotypic' and one 'lymphoid' cell lines whose proliferation was moderately inhibited by anti-G-CSF mAb. In contrast, the other five cell lines, which were not affected in their proliferation by anti-G-CSF mAb (less than 10% inhibition), showed intracellular G-CSF under detection limit of EIA. Thus, the positive correlation between % inhibition by anti-G-CSF mAb and the amount of intracellular G-CSF was speculated in each of cell lines, and in fact, the high correlation coefficient (r = 0.876) was demonstrated by linear regression analysis as shown in Figure 5 . These results provided an additional evidence that the G-CSF/G-CSFR interaction participate in an autocrine growth of Ph1-positive leukemic cell lines.
Effect of G-CSF on differentiation of Ph1-positive leukemic cell lines
To address whether G-CSF can induce differentiation of Ph1-positive leukemic cell lines, we examined changes in morphology and surface antigens (CD13, CD14, CD19, CD33 and CD34) in the presence of rhG-CSF (10 ng/ml) using representative cell lines classified into different types. No changes were observed in morphology and antigens expression at least up to 12 days (data not shown).
Discussion
Ph1-positive leukemia expresses the BCR-ABL chimeric protein as a result of translocation between the bcr gene on chromosome 22 and the abl gene on chromosome 9, which exerts strong tyrosine kinase activities and are directly implicated in their leukemogenesis. 37 In general, the proliferation, differentiation, and survival of normal hematopoietic cells are mainly regulated by hematopoietic growth factors. Human CML progenitors display a normal proliferative response to growth factors despite the fact that they survive in the serum-free medium, 38 whereas the ectopic expression of BCR-ABL proteins in murine factor-dependent cells disrupts the responsiveness to exogenously added growth factors. 39 Thus, implication of BCR-ABL proteins in the regulation of responses to growth factors is not fully elucidated.
It has been postulated that the targets of G-CSF include multipotent hematopoietic stem cells [10] [11] [12] in addition to myeloid precursors. We have recently reported that G-CSFR is expressed on leukemic cells with 11q23 translocations and their proliferation is frequently stimulated with G-CSF. 13 Since leukemias with either Ph1 or 11q23 translocations have their origin in the multipotent hematopoietic stem cells, the possibility has been raised that the G-CSF/G-CSFR interaction may participate in the growth regulation of Ph1-positive leukemia cells. We showed that G-CSFR is always expressed on Ph1- Inhibitory effect of anti-G-CSF mAb on proliferation of Ph1-positive leukemic cell lines. Inhibitory effects by different concentrations of anti-G-CSF mAb on proliferation of four 'myeloid', five 'biphenotypic', and three 'lymphoid' Ph1-positive leukemic cell lines and a T cell line (KOPT-5, negative control) were shown as the % positive leukemia cells independent of the cell types. Even in 'lymphoid' type Ph1-positive leukemia cells, G-CSFR was detected as observed in leukemic cells with 11q23 translocations. 13 Recently, de Lau et al 40 reported that the expression of G-CSFR is upregulated by E2A-Pbx1 fusion transcription factor generated from t(1;19) in pre-B ALL, suggesting that the ectopic expression of G-CSFR is induced by the fusion products of translocation and may contribute to the leukemogenesis. Larsen et al 41 and Kita et al 42 reported that mRNA of G-CSFR was detected in some ALL and frequently in CD7 + non T-ALL which is also believed to arise from the hematopoietic stem cell. In addition to these observations, we have previously demonstrated that B cell progenitors increased in the bone marrow of children with ALL in remission express G-CSFR, 31 suggesting that B lymphoid precursors immediately branching from the multipotential stem cell express G-CSFR. It is thus conceivable that the G-CSFR expression on Ph1-positive leukemia cells reflects the nature of their normal counter-
Figure 4
Retrieval of the inhibitory effect of anti-G-CSF mAb by the exogenous addition of G-CSF. The 3 H-thymide uptake assays were performed using KOPM-30 and KOPN-55bi in RPMI 1640 medium supplemented with 10% FCS (left) and in DMEM/F12 serum free medium (right) in the absence or presence of 10 g/ml anti-G-CSF mAb combined with or without different concentrations (10, 100 ng/ml) of rhG-CSF. The representative data from three separate experiments were shown with error bars. G-CSFR is reported to mediate both growth and differentiation signals through its different cytoplasmic domains. 43, 44 We showed that G-CSF promoted proliferation but not induced differentiation in Ph1-positive leukemic cells and that the proliferative response to G-CSF varied depending on the types. The triggering of proliferation by G-CSF was observed Leukemia most profoundly in 'biphenotypic', but much less in 'lymphoid' Ph1-positive leukemic cell lines. These data agree with our recent observations obtained in cell lines with 11q23 translocations, in which G-CSF stimulated the DNA synthesis of 'biphenotypic' type more efficiently than that of 'lymphoid' type cell lines. 13 Considering that the simultaneous expression of both lymphoid and myeloid antigens is characteristic of leukemia derived from multipotential hematopoietic stem cell 18 whose proliferation is known to be supported with G-CSF at least in the murine system, [10] [11] [12] 'biphenotypic' type is the most typical stem cell leukemia and thus may be highly responsive to G-CSF.
G-CSF is generally considered as a potent stimulator for myeloid lineage cells. However, 'myeloid' Ph1-positive leukemic cell lines demonstrated only a weak response to G-CSF compared with 'biphenotypic' cell lines. We previously reported that the culture supernatants of a 'myeloid' Ph1-positive leukemic cell line (KOPM-28) stimulated colony formation of normal bone marrow cells. 26 It is also reported that G-CSF supported growth of the blasts in some AML cases in an autostimulatory fashion. 45 These observations led us to hypothesize that, in 'myeloid' Ph1-positive leukemic cell lines, endogenously produced G-CSF is involved in an autocrine loop of proliferation and therefore exogenously added G-CSF is not fully stimulative. Our hypothesis was supported by experiments showing that neutralization of G-CSF secreted into culture supernatants by anti-G-CSF mAb partially inhibited their proliferation and that the substantial amount of intracellular G-CSF was detected in 'myeloid' Ph1-positive leukemic cell lines. The relatively low G-CSFR expression observed in 'myeloid' Ph1-positive leukemic cell lines might reflect the down-regulation of G-CSFR 46 as a consequence of continuous stimulation by endogenously produced G-CSF. Klein et al 47 reported a possible autocrine loop of G-CSF in myeloid progenitors from some CML patients. More recently, Jiang et al 48 also reported an autocrine loop of G-CSF within the leukemic CD34 + cells of patients with chronic-phase CML. Our data indicated that the autocrine loop of the G-CSF/G-CSFR interaction plays an important role, at least in part, in the growth regulation of not only progenitor cells from chronic phase CML but also leukemia cells from Ph1-positive acute leukemia and CML-BC particularly of 'myeloid' type.
In factor-dependent murine hematopoietic cell lines, ectopic expression of p210 BCR-ABL protein induced the factor-independent cell growth and the loss of their responsiveness to exogenous growth factors, in which the autocrine mechanism by growth factors was shown not to be involved. 39, 49 In contrast, in factor-dependent human leukemic M07E cells, introduction of p210 BCR-ABL protein by retroviral gene-transfer lost their requirement for growth factors, but did not completely abrogate their responsiveness to exogenously added growth factors and rather stimulated the autocrine loop by promoting their intrinsic production of growth factors. 50 Our data indicated that human Ph1-positive leukemic cells exhibited not only their responsiveness to exogenously added G-CSF (particularly in 'biphenotypic' type), but also their enhancement of proliferation via an autocrine loop of G-CSF (particularly in 'myeloid' type).
From the clinical point of view, our data suggest that the administration of G-CSF to Ph1-positive leukemia patients, particularly with 'biphenotypic' phenotype, might facilitate relapse of the disease. However, further clinical analysis will be required regarding the merits and demerits of G-CSF administration to Ph1-positive leukemia patients, since it may improve prognosis by preventing severe infections and/or shortening the interval between programs of chemotherapy as reported in AML. 51 On the other hand, it might be possible that G-CSF enhance the cytotoxic effect of anti-leukemic agents in Ph1-positive leukemia by promoting leukemic cells into chemotherapy-sensitive G 1 -and S-phases as attempted in AML cells. 52 Thus, it might be effective to use G-CSF together with preconditioning regimen in autologous or allogeneic bone marrow transplantation for Ph1-positive leukemia.
